Rethinking Rheumatoid Arthritis Management: Is Personalized Medicine the Future?

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects millions of people worldwide. This chronic inflammatory disorder leads to joint inflammation, severe pain, stiffness of joints, and disability [1]. Despite the great advancement in treatment strategies, the management of RA remains complex, with a significant proportion of patients failing to achieve long-term remission [2]. The conventional “one-size-fits-all” approach, mainly based on clinical symptoms and standard treatment protocols, has limitations [3]. As research in immunology and genomics expands, the concept of personalized medicine (PM) is gaining tremendous traction [4]. PM recognizes that RA is diverse and that each patient presents with a distinct biomarker profile, which, along with lifestyle and clinical aspects, could serve as a predictive biomarker for treatment outcomes [5], allowing for tailored patient management based on the principle of right drug, right patient, and right time.

The Need for a Personalized Approach

Present RA treatment regimens depend on disease-modifying antirheumatic drugs (DMARDs), biologics, and Janus kinase (JAK) inhibitors like tofacitinib and baricitinib [6]. Although these modalities have significantly transformed RA management, their effectiveness varies among individuals. Factors such as genetic predisposition, immune system variability, and environmental triggers have been reported to influence disease progression and treatment response [7,8]. PM aims to customize treatment plans according to an individual’s specific genetic, molecular, and clinical profile, thus improving efficacy and minimizing adverse effects [9].

Advances in Biomarkers and Precision Therapy

Recent studies have identified promising biomarkers for RA management. According to a study published in Nature Scientific report (2023) mentioned that, genetic markers such as HLA-DRB1 shared epitope alleles are strong predictors of RA susceptibility and severity [10]. Additionally, a 2019 study published in Advances in Rheumatology, BMC indicated that serum biomarkers such as anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) can significantly enhance early diagnosis and prognosis assessment [11]. Recently, advancements in molecular profiling methods revealed novel biomarkers associated with treatment responses, thereby setting the stage for targeted therapies. Studies published in various journals documented that RA patients with elevated interleukin-17 (IL-17) levels responded better to IL-17 inhibitors such as secukinumab, compared to traditional tumor necrosis factor inhibitors (TNFi) [12,13]. This emphasizes the importance of biomarker-driven treatment selection in order to enhance therapeutic efficacy.

The Role of Artificial Intelligence in Personalized Rheumatology

Artificial intelligence (AI) and machine learning (ML) are evolving as powerful tools in various disciplines of medical sciences including rheumatology [14]. By examining vast datasets, AI-driven algorithms are capable of predicting disease progression, identify treatment, and recommend optimal drug combination [15]. The study in Frontiers in medicine validated that machine learning models evaluating electronic health records (EHRs) could predict RA flares with utmost accuracy that enables proactive treatment adjustment [16]. In regard wearable devices like smart watches, fitness trackers and mobile applications like dexcom and fitbit have greatly transformed the patients monitoring system [17]. Studies found that continuous tracking of symptoms, inflammatory markers, and medication adherence through smart devices allowed for real-time treatment adjustments, leading to better disease control [18]. Digital health solutions not only empower patients but also bridge the gap between research and clinical practice.

Flowchart: Personalized RA Management Process

Step 1: Patient Diagnosis & Risk Assessment
→ Genetic & Biomarker Testing
→ Clinical History & Environmental Factors Analysis

Step 2: Classification Based on Biomarkers
→ High TNF-α Levels → TNF Inhibitors (Infliximab, Etanercept)
→ High IL-6 Levels → IL-6 Inhibitors (Tocilizumab)
→ High IL-17 Levels → IL-17 Inhibitors (Secukinumab)

Step 3: AI-Driven Treatment Optimization
→ Machine Learning Model Predicts Response Probability
→ Drug Selection Based on Patient Data

Step 4: Continuous Monitoring & Adjustments
→ Wearable Device & Mobile App Integration
→ Real-time Inflammation Tracking
→ Treatment Adjustment Recommendations

Challenges and Future Directions

Despite the great potential of PM in RA management, it faces numerous challenges. The integration of genetic and molecular profiling into routine clinical practice requires substantial investment and regulatory approval. Furthermore, the cost of precision therapies remains a great concern, which limits the accessibility of therapy [19]. A study published in BMC cancer (2021) advocated that while biomarker-driven treatment approaches can enhance patient outcomes; however, their high upfront expenses may limit their broad implementation [20]. Ethical issues such as data privacy and consent need to be carefully considered as the use of AI and big data analytics expands in rheumatology [21]. Nonetheless, continuous clinical trials and collaborative research efforts are leading toward a more tailored approach. The primary objective is to shift away from trial-and-error prescribing towards evidence-driven, customized treatment plans that enhance patient outcomes and quality of life.

The future of managing RA is rapidly heading towards PM. By utilizing genomics, biomarkers research, and AI-based analytics, rheumatologists can adopt a more precise, effective, and patient-focused treatment approach. Although there are several challenges persist, the transition from broad treatment methods to specific therapies offers significant potential to revolutionize RA management, minimize treatment failures, and improve long-term disease control. As research continues to advance, the practical application of personalized medicine may soon establish itself as the standard practice in rheumatology.n bronchiectasis predominance instead of honeycombing (Figure 5).

None.

No conflict of interest.

1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, et al. (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone research 6(1): 15.
2. Wang Z, Huang J, Xie D, He D, Lu A, et al. (2021) Toward overcoming treatment failure in rheumatoid arthritis. Frontiers in immunology 12: 755844.
3. Molla G, Bitew M (2024) Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines 12(12): 2750.
4. Goetz LH, Schork NJ (2018) Personalized medicine: motivation, challenges, and progress. Fertility and sterility 109(6): 952-963.
5. Sharma SD, Bluett J (2024) Towards personalized medicine in rheumatoid arthritis. Open Access Rheumatology: Research and Reviews 16: 89-114.
6. Tanaka Y (2021) Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology 60(Supplement_6): vi12-vi20.
7. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, et al. (2017) Genetic and environmental risk factors for rheumatoid arthritis. Best practice & research Clinical rheumatology 31(1): 3-18.
8. Alam M, Abbas K, Mustafa M, Usmani N, Habib S (2024) Microbiome-based therapies for Parkinson’s disease. Frontiers in Nutrition 11: 1496616.
9. Su J, Yang L, Sun Z, Zhan X (2024) Personalized drug therapy: innovative concept guided with proteoformics. Molecular & Cellular Proteomics 23(3).
10. Inoue M, Nagafuchi Y, Ota M, Tsuchiya H, Tateishi S, et al. (2023) Carriers of HLA-DRB1* 04: 05 have a better clinical response to abatacept in rheumatoid arthritis. Scientific Reports 13(1): 15250.
11. Rocha SDB, Baldo DC, Andrade LEC (2019) Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Advances in Rheumatology 59: 2.
12. Robert M, Miossec P (2019) IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Frontiers in medicine 5: 364.
13. Kellner H (2013) Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Therapeutic advances in musculoskeletal disease 5(3): 141-152.
14. Sequí-Sabater JM, Benavent D (2025) Artificial intelligence in rheumatology research: what is it good for?. RMD open 11(1): e004309.
15. Vora LK, Gholap AD, Jetha K, Thakur RR S, Solanki HK, et al. (2023) Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics 15(7): 1916.
16. Gilvaz VJ, Reginato AM (2023) Artificial intelligence in rheumatoid arthritis: potential applications and future implications. Frontiers in medicine 10: 1280312.
17. Jafleh EA, Alnaqbi FA, Almaeeni HA, Faqeeh S, Alzaabi MA, et al. (2024) The role of wearable devices in chronic disease monitoring and patient care: a comprehensive review. Cureus 16(9): e68921.
18. Chan AHY, Foot H, Pearce CJ, Horne R, Foster JM, et al. (2022) Effect of electronic adherence monitoring on adherence and outcomes in chronic conditions: a systematic review and meta-analysis. PLoS One 17(3): e0265715.
19. Burgos PI, Danila MI, Kelley JM, Hughes LB, Bridges Jr, et al. (2009) Understanding personalized medicine in rheumatoid arthritis: a clinician’s guide to the future. Therapeutic advances in musculoskeletal disease 1(2): 97-105.
20. Seo MK, Cairns J (2021) How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. BMC cancer 21(1): 980.
21. Farhud DD, Zokaei S (2021) Ethical issues of artificial intelligence in medicine and healthcare. Iranian journal of public health 50(11).